Poly-ADP ribose polymerase (PARP) inhibitors are approved drugs for tumours harbouring mutations in either BRCA1 or BRCA2. Furthermore, previous research has shown that p53—which was one of the key cancer drivers in the present EP cohort—regulates key processes of HRR, and interacts directly with BRCA2 [59, 60]. This evidence concerns the gene BRCA2 and cancer.